Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,028,754
  • Shares Outstanding, K 104,775
  • Annual Sales, $ 482,380 K
  • Annual Income, $ 106,140 K
  • EBIT $ 143 M
  • EBITDA $ 137 M
  • 60-Month Beta 0.45
  • Price/Sales 12.15
  • Price/Cash Flow 58.38
  • Price/Book 9.17

Options Overview Details

View History
  • Implied Volatility 64.68% ( -2.60%)
  • Historical Volatility 49.64%
  • IV Percentile 35%
  • IV Rank 35.56%
  • IV High 156.92% on 05/17/24
  • IV Low 13.78% on 08/16/24
  • Put/Call Vol Ratio 0.23
  • Today's Volume 108
  • Volume Avg (30-Day) 1,539
  • Put/Call OI Ratio 1.06
  • Today's Open Interest 34,152
  • Open Int (30-Day) 34,712

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.37
  • Number of Estimates 4
  • High Estimate 0.44
  • Low Estimate 0.28
  • Prior Year 0.28
  • Growth Rate Est. (year over year) +32.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.01 +36.97%
on 10/31/24
61.66 -6.69%
on 11/08/24
+8.62 (+17.62%)
since 10/22/24
3-Month
33.34 +72.59%
on 09/04/24
61.66 -6.69%
on 11/08/24
+23.26 (+67.85%)
since 08/22/24
52-Week
20.84 +176.10%
on 04/22/24
61.66 -6.69%
on 11/08/24
+32.20 (+127.07%)
since 11/22/23

Most Recent Stories

More News
Corcept Shares Rise More Than 60% in Three Months: Here's Why

Shares of Corcept Therapeutics Incorporated CORT have rallied 60.7% in the past three months against the industry’s decline of 9.9%.The company’s sole-marketed drug, Korlym (mifepristone), which is...

CORT : 57.54 (+2.90%)
IMCR : 32.28 (+0.50%)
CSTL : 29.81 (+3.22%)
SPRO : 1.1600 (-2.52%)
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance

For Immediate ReleaseChicago, IL – November 11, 2024 – Today, Zacks Equity Research like Madrigal Pharmaceuticals MDGL, Corcept Therapeutics CORT, Catalyst Pharmaceuticals CPRX, Larimar Therapeutics...

CORT : 57.54 (+2.90%)
TBPH : 9.47 (-1.46%)
MDGL : 347.45 (+5.53%)
LRMR : 6.16 (+0.49%)
CPRX : 21.48 (+1.70%)
5 Small Drug Stocks to Buy as Trump Gets Re-Elected

The drug industry witnessed major policy changes during Joe Biden's four-year term as U.S. President, including the historic Inflation Reduction Act (“IRA”). With Donald Trump’s reelection, the biotech...

CORT : 57.54 (+2.90%)
TBPH : 9.47 (-1.46%)
MDGL : 347.45 (+5.53%)
LRMR : 6.16 (+0.49%)
CPRX : 21.48 (+1.70%)
5 Stocks With Recent Price Strength to Tap Wall Street Rally

U.S. stock markets started November, adding more steam to the ongoing rally. The primary reason was the anticipation of Donald Trump becoming the 47th president of the country. On Nov 5, Trump clinched...

CORT : 57.54 (+2.90%)
SEZL : 463.98 (+4.02%)
CDXC : 7.44 (-2.49%)
TILE : 25.46 (+0.99%)
BGC : 9.60 (-5.51%)
Corcept Therapeutics Stock Surges 61% in 2024: A Must Buy?

Corcept Therapeutics Incorporated CORT has been having a fabulous 2024, with its share price increasing 60.5% year to date as of Nov. 5, 2024.This company engages in the discovery and development of drugs...

CORT : 57.54 (+2.90%)
COLL : 29.96 (-1.48%)
IONS : 34.01 (+0.21%)
New Strong Buy Stocks for November 5th

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:American Assets Trust, Inc. AAT: This self-administered real estate investment trust has seen the Zacks Consensus Estimate for its...

QUAD : 7.01 (+3.24%)
CORT : 57.54 (+2.90%)
ADT : 7.54 (unch)
AAT : 28.08 (+0.86%)
CMA : 71.09 (+3.18%)
Corcept Trumps Q3 Earnings & Sales Estimates, Ups '24 Revenue View

Corcept Therapeutics Incorporated CORT reported third-quarter 2024 earnings of 41 cents per share, which significantly beat the Zacks Consensus Estimate of 27 cents. The company had reported earnings of...

FOLD : 9.66 (+1.68%)
CORT : 57.54 (+2.90%)
ARDX : 5.31 (+3.71%)
ATNM : 1.4500 (-1.36%)
Corcept: Q3 Earnings Snapshot

Corcept: Q3 Earnings Snapshot

CORT : 57.54 (+2.90%)
Zacks.com featured highlights Idaho Strategic, Qifu, Sezzle, Corcept and FinWise

For Immediate ReleaseChicago, IL – October 23, 2024 – Stocks in this week’s article are Idaho Strategic Resources Inc. IDR, Qifu Technology Inc. QFIN, Sezzle Inc. SEZL, Corcept Therapeutics Inc....

CORT : 57.54 (+2.90%)
SEZL : 463.98 (+4.02%)
IDR : 11.85 (-0.67%)
FINW : 17.83 (+0.68%)
QFIN : 34.53 (-1.93%)
5 Stocks With Recent Price Strength to Tap Wall Street Rally

September and October are known as the most disrupting months on Wall Street. Surprisingly, this year, September was quite favorable for market participants. An aggressive 50 basis-point interest rate...

CORT : 57.54 (+2.90%)
SEZL : 463.98 (+4.02%)
IDR : 11.85 (-0.67%)
FINW : 17.83 (+0.68%)
QFIN : 34.53 (-1.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 59.68
2nd Resistance Point 58.69
1st Resistance Point 58.12
Last Price 57.54
1st Support Level 56.55
2nd Support Level 55.56
3rd Support Level 54.99

See More

52-Week High 61.66
Last Price 57.54
Fibonacci 61.8% 46.07
Fibonacci 50% 41.25
Fibonacci 38.2% 36.43
52-Week Low 20.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar